Phase 2 N=69 Addition of Opaganib to Androgen Antagonists in Patients With mCRPC
Prostate Cancer
Primary: Disease Control Status — 4; 3; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=102 Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy
Non-small Cell Lung Cancer
Primary: Number of Patients With Grade 3 and Grade 4 Possibly-related Adverse Events (PRAEs) — 5; 5; 10 Participants
Phase 2 N=18 A Clinical Trial of Epizon-701 (EPN-701) in Subjects With End-Stage Renal Disease (ESRD)
End-Stage Renal Disease (ESRD)
Primary: Number of Participants With Adverse Events (AEs) — 8 participants
Phase 2 N=74 Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors
Neuroendocrine Tumors · Hepatic Metastases · Metastases
Primary: Rate of Hepatic Progression Free Survival at 24 Months — 47; 20 Participants
Phase 2 N=205 Hidradenitis Suppurativa Phase 2b Study of Izokibep
Hidradenitis Suppurativa
Primary: Part A: Number of Participants Who Achieved Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 12 — 12 Participants
Phase 2 N=100 RANKL-blockade for the Treatment of Erosive Osteoarthritis (OA) of Interphalangeal Finger Joints
Hand Osteoarthritis
Primary: Total Ghent University Scoring System (GUSS) of Target Joints at Week 24 — 162.2; 153.3 units on a scale — p=0.024
Phase 2 N=155 Paxlovid for Treatment of Long Covid
Post-acute Sequelae of SARS-CoV-2 Infection · Long COVID
Primary: Number of Participants With No, Mild, Moderate, or Severe Symptoms at Week 10 According to the Core Symptoms Severity Scale Score — 3; 4; 22; 17 Participants — p=0.903
Phase 2 N=43 A Study of Patients Receiving High-Dose Rate Brachytherapy
Cervical Cancer · Endometrial Cancer · Esophageal Cancer
Primary: Number of Participants Who Had Adequate High-Quality Brachytherapy Implants Reported Per Strata (Four Body Sites) and Combined Overall — 27; 0; 0; 14 Participants
Phase 2 N=48 Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma
Ann Arbor Stage II Follicular Lymphoma · Ann Arbor Stage II Marginal Zone Lymphoma · Ann Arbor Stage III Follicular Lymphoma
Primary: Progression Free Survival (PFS) — 71.2; 54.2 percentage of participants
Phase 2 N=33 Erythrocytes-Mediated Delivery Of Dexamethasone 21-Phosphate In Steroid-Dependent Ulcerative Colitis
Ulcerative Colitis
Primary: The Proportion of Patients Responders to Dex 21-P vs Placebo — 15; 1; 6; 11 Participants — p=<0.001
Phase 2 N=244 Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus (SLE)
Primary: Number of Participants With a SLE Responder Index (SRI-4) Response at Week 52 — 26; 29; 21; 35 Participants
Phase 2 N=67 A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis
Crohn Disease · Ulcerative Colitis
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 18; 19; 2; 2 Participants
Phase 2 N=61 A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus
Lichen Sclerosus
Primary: Percentage of Participants With ITCH4 at Week 12 — 35.7; 40.0 percentage of participants — p=0.737
Phase 2 N=1,068 Endotracheal Tubes to Prevent Ventilator-Associated Pneumonia
Ventilator-acquired Pneumonia
Primary: Quality of Life - 36-item Short-Form General Health Survey — 40.5; 40.0; 48.9; 45.9 score on a scale — p=0.78
Phase 2 N=35 A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
Primary: Impact of MN-166 on [11C]-PBR28 Uptake in the Motor Cortices and Brain Stem Measured by Positron Emission Tomography (PET) Imaging at 12 - 24 Weeks — 0.0015 SUV ratio